Dr Reddy’s Laboratories saw a high single-digit revenue increase in Q3, driven by India, emerging, and European markets, despite a muted US business. The company launched 24 new products, with a pipeline of 100 products expected to offset slowing Revlimid sales. Analysts remain cautious, with valuations factoring in earnings upside.
Is the smallcap rally a trap? Only 37% of stocks are outperforming their benchmark
India’s recent smallcap surge indicates that less stock is outpacing the benchmark index, revealing a narrowing group of successful stocks boosting overall returns. Conversely, largecap
August 25, 2026